John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive


The contribution of a sustained angiogenesis inhibition in metastatic colorectal cancer (mCCR) treatment. Introduction to maintenance concept beyond progression Volume 19, issue 7, Septembre 2012


See all figures

Institut de Cancérologie de l’Ouest, Bd J Monod, 44 805 Nantes, France, Hôpital Saint-Antoine, service d’oncologie médicale, Paris, France

This review traces a new concept of treatment in metastatic colo-rectal cancer called “sustained angiogenesis inhibition beyond progression”. In clinical practice, a multiline strategy is commonly defined, using each active drug in sequential therapeutic schedules. The clinical benefit demonstration of maintaining anti-angiogenic therapy beyond progression while switching chemotherapy across multiple lines allows to validate a new therapeutic strategy in mCCR.